Keros Therapeutics (KROS) said Tuesday it has agreed to provide Takeda Pharmaceutical (TAK) with a global commercial license for elritercept, as well as to collaborate on the drug candidate's development.
Keros said it expects to receive an upfront payment of $200 million, with milestone payments that could reach up to $1.1 billion. It also expects to receive tiered royalties on net sales.
The upfront payment would extend Keros' operational runway through Q4 of 2028, the company said.
The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, Keros said.
Elritercept is currently in late-stage clinical trials for myelodysplastic syndrome and myelofibrosis, according to Keros.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。